246 related articles for article (PubMed ID: 25548153)
21. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
23. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Hinrichs CS; Palmer DC; Rosenberg SA; Restifo NP
J Immunother; 2005; 28(6):517-24. PubMed ID: 16224268
[TBL] [Abstract][Full Text] [Related]
24. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-155 deficiency in CD8+ T cells inhibits its anti-glioma immunity by regulating FoxO3a.
Qiu C; Ma J; Wang ML; Zhang Q; Li YB
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2486-2496. PubMed ID: 30964175
[TBL] [Abstract][Full Text] [Related]
27. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling.
Gracias DT; Stelekati E; Hope JL; Boesteanu AC; Doering TA; Norton J; Mueller YM; Fraietta JA; Wherry EJ; Turner M; Katsikis PD
Nat Immunol; 2013 Jun; 14(6):593-602. PubMed ID: 23603793
[TBL] [Abstract][Full Text] [Related]
28. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
[No Abstract] [Full Text] [Related]
29. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
30. MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.
He W; Wang C; Mu R; Liang P; Huang Z; Zhang J; Dong L
Oncogene; 2017 Jul; 36(29):4212-4223. PubMed ID: 28346427
[TBL] [Abstract][Full Text] [Related]
31. Cytokine-like molecule CCDC134 contributes to CD8⁺ T-cell effector functions in cancer immunotherapy.
Huang J; Xiao L; Gong X; Shao W; Yin Y; Liao Q; Meng Y; Zhang Y; Ma D; Qiu X
Cancer Res; 2014 Oct; 74(20):5734-45. PubMed ID: 25125657
[TBL] [Abstract][Full Text] [Related]
32. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.
Xin G; Khatun A; Topchyan P; Zander R; Volberding PJ; Chen Y; Shen J; Fu C; Jiang A; See WA; Cui W
Cancer Immunol Res; 2020 Jan; 8(1):7-18. PubMed ID: 31719059
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
34. Development of antitumor immune responses in reconstituted lymphopenic hosts.
Hu HM; Poehlein CH; Urba WJ; Fox BA
Cancer Res; 2002 Jul; 62(14):3914-9. PubMed ID: 12124318
[TBL] [Abstract][Full Text] [Related]
35. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling.
Tennant MD; New C; Ferreira LMR; O'Neil RT
Mol Ther; 2023 Sep; 31(9):2591-2599. PubMed ID: 37481703
[TBL] [Abstract][Full Text] [Related]
36. The MicroRNA miR-191 Supports T Cell Survival Following Common γ Chain Signaling.
Lykken EA; Li QJ
J Biol Chem; 2016 Nov; 291(45):23532-23544. PubMed ID: 27634043
[TBL] [Abstract][Full Text] [Related]
37. miR-155 releases the brakes on antitumor T cells.
Ji Y; Gattinoni L
Oncoimmunology; 2015 Aug; 4(8):e1026533. PubMed ID: 26405586
[TBL] [Abstract][Full Text] [Related]
38. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts.
Cui Y; Zhang H; Meadors J; Poon R; Guimond M; Mackall CL
Blood; 2009 Oct; 114(18):3831-40. PubMed ID: 19704119
[TBL] [Abstract][Full Text] [Related]
39. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
Ji Y; Hocker JD; Gattinoni L
Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
[TBL] [Abstract][Full Text] [Related]
40. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
Su EW; Moore CJ; Suriano S; Johnson CB; Songalia N; Patterson A; Neitzke DJ; Andrijauskaite K; Garrett-Mayer E; Mehrotra S; Paulos CM; Doedens AL; Goldrath AW; Li Z; Cole DJ; Rubinstein MP
Sci Transl Med; 2015 Oct; 7(311):311ra170. PubMed ID: 26511507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
